Market Research Logo

Anti-Obesity Prescription Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

Anti-Obesity Prescription Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

The report on global anti-obesity prescription drugs market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global anti-obesity prescription drugs market to grow with a CAGR of 4.97% over the forecast period of 2018-2024. The study on anti-obesity prescription drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024. According to the study, the global anti-obesity prescription drugs market is promoted by factor such as rising cases of obesity worldwide, substantial rise in incidences of chronic diseases due to obesity and increased work load and stress. On the other hand a stringent regulation by the FDA is one of the restraining factors negatively affecting the growth in the market over the forecast period.

The report on anti-obesity prescription drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global anti-obesity prescription drugs market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global anti-obesity prescription drugs market over the period of 2016 to 2024. Further, IGR- Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Research Methodology
A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through
1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers
Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global anti-obesity prescription drugs market is segmented on the basis of drug class, distribution channel and age group.

Global Anti-obesity Prescription Drugs Market by Drug Class
Orlistat
Phentermine And Topiramate
Bupropion And Naltrexone
Lorcaserin
Liraglutide
Global Anti-obesity Prescription Drugs Market by Distribution Channel
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Global Anti-obesity Prescription Drugs Market by Age Group
Pediatric
Adult

Company Profiles
F Hoffmann La Roche Ltd
Orexigen Therapeutics, Inc
Novo Nordisk A/S
Arena Pharmaceuticals, Inc
GlaxoSmithKline
VIVUS, Inc
Boehringer Ingelheim
Alizyme
Others

How this report delivers?
1. Comprehensive analysis of global as well as regional markets of anti-obesity prescription drugs market.
2. Complete coverage of all the segments in anti-obesity prescription drugs market to analyze the trends, developments in the global market and forecast of market size up to 2024.
3. Comprehensive analysis of the companies operating in global anti-obesity prescription drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.


The report on global anti-obesity prescription drugs market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global anti-obesity prescription drugs market to grow with a CAGR of 4.97% over the forecast period of 2018-2024. The study on anti-obesity prescription drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Global Anti-obesity Prescription Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. IGR-Growth Matrix Analysis
3.5. Competitive Landscape in the Global Anti-obesity Prescription Drugs Market
4. Global Anti-obesity Prescription Drugs Market by Drug Class
4.1. Orlistat
4.2. Phentermine and Topiramate
4.3. Bupropion and Naltrexone
4.4. Lorcaserin
4.5. Liraglutide
5. Global Anti-obesity Prescription Drugs Market by Distribution Channel
5.1. Retail Pharmacy
5.2. Hospital Pharmacy
5.3. Online Pharmacy
6. Global Anti-obesity Prescription Drugs Market by Age Group
6.1. Pediatric
6.2. Adult
7. Global Anti-obesity Prescription Drugs Market by Region 2018-2024
7.1. North America
7.1.1. North America Anti-obesity Prescription Drugs Market by Drug Class
7.1.2. North America Anti-obesity Prescription Drugs Market by Distribution Channel
7.1.3. North America Anti-obesity Prescription Drugs Market by Age Group
7.1.4. North America Anti-obesity Prescription Drugs Market by Country
7.2. Europe
7.2.1. Europe Anti-obesity Prescription Drugs Market by Drug Class
7.2.2. Europe Anti-obesity Prescription Drugs Market by Distribution Channel
7.2.3. Europe Anti-obesity Prescription Drugs Market by Age Group
7.2.4. Europe Anti-obesity Prescription Drugs Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Anti-obesity Prescription Drugs Market by Drug Class
7.3.2. Asia-Pacific Anti-obesity Prescription Drugs Market by Distribution Channel
7.3.3. Asia-Pacific Anti-obesity Prescription Drugs Market by Age Group
7.3.4. Asia-Pacific Anti-obesity Prescription Drugs Market by Country
7.4. RoW
7.4.1. RoW Anti-obesity Prescription Drugs Market by Drug Class
7.4.2. RoW Anti-obesity Prescription Drugs Market by Distribution Channel
7.4.3. RoW Anti-obesity Prescription Drugs Market by Age Group
7.4.4. RoW Anti-obesity Prescription Drugs Market by Sub-region
8. Company Covered
8.1. F Hoffmann La Roche Ltd
8.2. Orexigen Therapeutics, Inc
8.3. Novo Nordisk A/s
8.4. Arena Pharmaceuticals, Inc
8.5. Glaxosmithkline
8.6. Vivus, Inc
8.7. Boehringer Ingelheim
8.8. Alizyme
8.9. Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report